Business Description
Chimeric Therapeutics Ltd
ISIN : AU0000121576
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.85 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 1.46 | |||||
Debt-to-EBITDA | -0.3 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40.5 | |||||
3-Year EPS without NRI Growth Rate | 38.4 | |||||
3-Year FCF Growth Rate | 47.3 | |||||
3-Year Book Growth Rate | -65.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.95 | |||||
9-Day RSI | 38.35 | |||||
14-Day RSI | 37.74 | |||||
6-1 Month Momentum % | -50 | |||||
12-1 Month Momentum % | -67.86 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.32 | |||||
Quick Ratio | 0.32 | |||||
Cash Ratio | 0.3 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.7 | |||||
Shareholder Yield % | -111.56 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -170.91 | |||||
ROA % | -58.43 | |||||
ROIC % | -128.01 | |||||
ROC (Joel Greenblatt) % | -8198.21 | |||||
ROCE % | -124.56 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2 | |||||
EV-to-EBIT | -0.82 | |||||
EV-to-Forward-EBIT | -0.86 | |||||
EV-to-EBITDA | -0.82 | |||||
EV-to-Forward-EBITDA | -0.71 | |||||
EV-to-FCF | -1.33 | |||||
Earnings Yield (Greenblatt) % | -121.95 | |||||
FCF Yield % | -79.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return %
Total Annual Return %
Chimeric Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.018 | ||
Beta | 2.01 | ||
Volatility % | 68.21 | ||
14-Day RSI | 37.74 | ||
14-Day ATR (A$) | 0.001085 | ||
20-Day SMA (A$) | 0.00755 | ||
12-1 Month Momentum % | -67.86 | ||
52-Week Range (A$) | 0.006 - 0.043 | ||
Shares Outstanding (Mil) | 1,575.15 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Chimeric Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Chimeric Therapeutics Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Chimeric Therapeutics Ltd Frequently Asked Questions
What is Chimeric Therapeutics Ltd(ASX:CHM)'s stock price today?
When is next earnings date of Chimeric Therapeutics Ltd(ASX:CHM)?
Does Chimeric Therapeutics Ltd(ASX:CHM) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |